TRACER

Principal Investigator:
Safwan Kassas, MD           (Covenant)
Alok Maheshwari, MD        (St. Marys)
Daniel Lee, MD                 (Bay Med)
William Felten, MD            (Midland)

Sub-Investigators:
William Felten, MD                                    Gregory Pellizzon, MD
Kondaramvalappil Ravindran, MD           Umesh Badami, MD
Manoj Sharma, MD                                    Peter Fattal, MD
Susan Sallach, MD                                    John Collins, MD
Shiraz Shariff, MD                                   Rao Gudipati, MD
Stephen Mattichak, MD                            Nilofar Islam, MD
Rami Safadi, MD                                      Tanveer Malik MD
Robert Genovese MD                              Edwin Flattery, PA-C

Sponsor:
Schering-Plough Research Institute, a Division of Schering Corporation

Study Purpose:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)

Objective:
To evaluate the hypothesis that SCH 530348 added to standard of care will reduce the incidence of atherothrombotic ischemic events relative to standard of care alone, as measured by the composite of cardiovascular death, myocardial infarction (MI), stroke, recurrent ischemia with rehospitalization, and urgent coronary revascularization.

Status:
Active enrollment

If you have any questions, please feel free to contact the coordinators, and they will be happy to answer any questions you have regarding this study.

<< Back